Actos Lawsuit 2026: the $2.4 Billion Bladder-Cancer Settlement — and the New RICO Class Action

Takeda paid about $2.4 billion in 2015 to settle roughly 9,000 Actos bladder-cancer lawsuits, after the FDA warned that long-term use of the diabetes drug raised bladder-cancer risk by about 40 percent. The old MDL is closed, but in 2026 a new certified national class action is moving forward with no settlement yet.

Key facts

  • Actos (pioglitazone), a Type 2 diabetes drug, has been sold in the United States since 1999 and at its peak generated billions in annual revenue for Takeda.
  • A 10-year Kaiser Permanente study begun in 2002 found a 40% higher bladder-cancer risk in patients who took Actos for more than a year; the FDA added warnings in 2011.
  • France and Germany suspended or restricted Actos over the bladder-cancer concern.
  • In 2015, Takeda agreed to pay up to $2.4 billion to resolve about 9,000 lawsuits, with reports putting the per-case figure above $296,000 at 95% claimant participation.
  • Of nine lawsuits tried, five verdicts favored Takeda and four favored plaintiffs — including a $2 million-plus award to Frances Wisniewski.

What Actos is — and what the bladder-cancer link means

Actos is the brand name for pioglitazone, a prescription medicine for Type 2 diabetes that helps the body use insulin more effectively. Bladder cancer is a cancer that begins in the lining of the bladder; its established risk factors include smoking and certain chemical exposures. The lawsuits alleged that Takeda knew from its own research that long-term Actos use raised bladder-cancer risk, and hid that risk from patients and doctors. Takeda denied liability in the settlement.

The science the FDA acted on

The regulatory turning point came from a 10-year observational study by Kaiser Permanente Northern California, launched in 2002, which found that patients who took Actos regularly for more than a year faced roughly a 40% increase in bladder-cancer risk. On that basis, the FDA required a label update in 2011 warning that use for longer than a year may be associated with an increased risk. Regulators in France and Germany went further, suspending or sharply restricting the drug. Later FDA communications underscored that even shorter exposures could carry risk, though the strongest signal remained in long-term users.

The $2.4 billion settlement, explained

With thousands of cases consolidated in a federal multidistrict litigation (MDL) — a procedure that coordinates similar federal lawsuits before one judge while keeping each case individual — Takeda reached a settlement in 2015 covering roughly 9,000 bladder-cancer lawsuits. The deal was structured around participation thresholds: if at least 95% of eligible claimants opted in, Takeda would pay; at 97% or more, the total would reach $2.4 billion. Reported figures put the per-case payment above $296,000. Compensation varies widely by case, and most individual settlement amounts were never disclosed publicly. The MDL is now closed — cases against Takeda over Actos can no longer be filed through it.

The trials that shaped the deal

Before settling, both sides tested their cases in court. Nine Actos lawsuits went to trial: five verdicts went to Takeda, and four to plaintiffs. The plaintiff verdicts included Frances Wisniewski, a retired accountant from Pennsylvania whose three-week trial featured evidence that Takeda had destroyed documents related to the drug's development and marketing; the jury awarded her more than $2 million. Takeda argued at trial that other factors, such as smoking, explained the cancers. The mixed trial record is typical of mass torts: neither side wins everywhere, which is precisely what pushes both toward a global resolution.

New in 2026: the Painters v. Takeda class action

A distinct new case is now the one to watch. Painters v. Takeda is a certified national class action brought on behalf of third-party payors — insurers, health plans, and benefit funds that paid for Actos — alleging that Takeda concealed the bladder-cancer risk in violation of the federal RICO statute. In 2026 the case moved through its notice phase: the court approved the class-notice plan in February, notice issued on March 6, 2026, and the opt-out deadline passed on April 6, 2026. Important context: there is no settlement yet and no money available — no claims-filing process is open, and class members are being told to monitor the settlement website for future announcements.

Can you still file an Actos claim in 2026?

The 2015 MDL settlement is closed, and lawsuits against Takeda over Actos can no longer join it. New individual lawsuits may still be possible in state courts, but the statute of limitations is the decisive question — and for a drug whose risk has been publicly warned about since 2011, that clock has run out for most potential plaintiffs. A few narrow paths can still exist: recently diagnosed patients in states with discovery rules, or claims tied to the newer legal theories. Because the window is so tight, anyone who believes Actos caused their bladder cancer should consult a qualified attorney immediately rather than assuming eligibility either way.

What filing a claim usually looks like

Attorneys handling pharmaceutical cases typically work on contingency, so there is no upfront legal fee; they are paid only if they recover compensation. Expect to provide pharmacy records proving Actos prescriptions, medical records documenting the bladder-cancer diagnosis, and a timeline of use. The attorney's first job is triage: does the claim belong to an open proceeding (like the 2026 class action, if you are a payor), a viable state-court filing, or a closed chapter? That evaluation is normally free, and it is the only reliable answer to the question of whether a claim can still move forward.

For a clear video explainer of how mass-tort pharmaceutical cases work, the Problem Solved channel covers consumer legal topics in plain language.

Related reading: Invokana Lawsuit 2026, Pradaxa Lawsuit 2026, Belviq Lawsuit 2026.

Who Benefits From This — and Who Does Not

Who benefits most from this guide:

Third-party payors, such as insurers and health plans, in the Painters v. Takeda class action. How: it is a certified national class action alleging Takeda concealed Actos bladder-cancer risks in violation of RICO, and class notice issued March 6, 2026.

Individuals with a recently discovered bladder-cancer claim where the statute of limitations is still open. How: a few narrow paths can still exist, but the limitations question is decisive, so a lawyer should evaluate the timeline at once.

People with a documented history of taking Actos for more than a year before a bladder-cancer diagnosis. How: the 10-year Kaiser Permanente study begun in 2002 found a 40 percent higher bladder-cancer risk in patients who took Actos for more than a year, and the FDA added warnings in 2011.

Who does not benefit:

Anyone hoping to join the 2015 Actos settlement. How: that settlement of about 9,000 cases is closed and fully administered, and no new claimants can enter it.

Most people whose claims date back many years. How: with the risk publicly warned about since 2011, the clock has run out for most potential plaintiffs.

Anyone starting or stopping a prescribed diabetes medication because of litigation news. How: pioglitazone remains available in some markets with strict FDA warnings, and medication changes belong with your doctor, not with a lawsuit headline.

For a diabetes-drug litigation that is still in its pretrial phase, see our guide to the Ozempic ileus lawsuit, where no settlement has been announced.

Frequently asked questions

Is there still money available from the Actos settlement?

The 2015 settlement of about 9,000 cases is closed and fully administered. The only live proceeding is the 2026 Painters v. Takeda third-party-payor class action, which has no settlement and no open claims process yet.

How much did individual Actos plaintiffs receive?

Compensation varies widely by case, and most settlements are confidential. Under the 2015 deal's reported terms, the per-case figure exceeded $296,000 at 95% participation; individual amounts depended on injury severity and other case-specific factors.

Is Actos still on the market?

Pioglitazone remains available in some markets with strict FDA warnings, but regulators in France and Germany suspended or restricted it over the cancer concern. Never start or stop a prescribed diabetes medication based on litigation news; discuss any concern with your doctor.

What is the Painters v. Takeda case?

It is a certified national class action by third-party payors (insurers and health plans) alleging Takeda concealed Actos bladder-cancer risks in violation of RICO. Class notice issued March 6, 2026, the opt-out deadline passed April 6, 2026, and no settlement or claims process exists yet.

Who benefits from the new Actos class action?

Third-party payors benefit, because Painters v. Takeda is a certified national class action by insurers and health plans alleging Takeda concealed Actos bladder-cancer risks in violation of RICO. It has no settlement and no open claims process yet.

Who cannot join the Actos settlement anymore?

Nobody can join the 2015 settlement now, because it resolved about 9,000 cases and is closed and fully administered. New individual lawsuits may still be possible in state courts, but only where the statute of limitations is still open.

Disclaimer: This article is general information about public litigation, not legal or medical advice. For advice about your situation, consult a qualified attorney or your doctor.

Watch on YouTube

Problem Solved on YouTube